# Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC

> **NCT06709274** · NA · NOT_YET_RECRUITING · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 342 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Alectinib
- **DRUG:** TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy

## Key facts

- **NCT ID:** NCT06709274
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11
- **Primary completion:** 2029-01
- **Final completion:** 2032-01
- **Target enrollment:** 342 (ESTIMATED)
- **Last updated:** 2024-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06709274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06709274, "Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06709274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*